Tan-67 is a selective non-peptidic d-opioid receptor (DOR) agonist that confers neuroprotection against cerebral ischemia/reperfusion (I/R)-caused neuronal injury in pre-treated animals. In this study, we examined whether post-ischemic administration of Tan-67 in stroke mice is also neuroprotective and whether the treatment affects expression, maturation and processing of the amyloid precursor protein (APP). A focal cerebral I/R model in mice was induced by middle cerebral artery occlusion for 1 h and Tan-67 (1.5, 3 or 4.5 mg/kg) was administered via the tail vein at 1 h after reperfusion. Alternatively, naltrindole, a selective DOR antagonist (5 mg/ kg), was administered 1 h before Tan-67 treatment. Our results showed that post-ischemic administration of Tan-67 (3 mg/kg or 4.5 mg/kg) was neuroprotective as shown by decreased infarct volume and neuronal loss following I/R. Importantly, Tan-67 improved animal survival and neurobehavioral outcomes. Conversely, naltrindole abolished Tan-67 neuroprotection in infarct volume. Tan-67 treatment also increased APP expression, maturation and processing in the ipsilateral penumbral area at 6 h but decreased APP expression and maturation in the same brain area at 24 h after I/R. Tan-67-induced increase in APP expression was also seen in the ischemic cortex at 24 h following I/R. Moreover, Tan-67 attenuated BACE-1 expression, b-secretase activity and the BACE cleavage of APP in the ischemic cortex at 24 h after I/R, which was abolished by naltrindole. Our data suggest that Tan-67 is a promising DOR-dependent therapeutic agent for treating I/R-caused disorder and that Tan-67-mediated neuroprotection may be mediated via modulating APP expression, maturation and processing, despite an uncertain causative relationship between the altered APP and the outcomes observed.
Stroke causes high mortality and disability and is a major health problem worldwide. The majority of strokes are ischemic and occur when a blood clot blocks the blood supply to the brain, leading to neuronal injury and functional disability (O'Donnell et al. 2016) . Given its public health importance, it is striking that tissue plasminogen activator (tPA), a protein that breaks down blood clots and reopens an occluded artery, is still the only Food and Drug Administration-approved drug for treating acute ischemic stroke in the United States (Liang et al. 2014) . However, the utilization of tPA in ischemic stroke has some important limitations including narrow eligibility and treatment windows (Chapman et al. 2014) . Therefore, additional therapeutic agents for treating ischemic stroke are in urgent need.
Stroke survivors usually develop dementia and share some similar neuropathological features with Alzheimer's disease (AD), containing altered amyloid precursor protein (APP) processing and b-amyloid (Ab) accumulation (Shi et al. 2000; Badan et al. 2004) . APP is a transmembrane glycoprotein that can be proteolytically cleaved by b-and c-secretases to produce Ab fragments and are implicated in AD (Panegyres 2001) . It has been reported that APP is both N-and O-glycosylated (Saito et al. 1993; Pahlsson and Spitalnik 1996) . The mature form (mAPP) of APP is an N-/O-glycosylated species concentrated in the trans-Golgi/ plasma membrane. The immature form of APP (imAPP) is predominantly N-glycosylated and localized in the endoplasmic reticulum and cis-Golgi (Su et al. 2003) . The majority of APP cleavage by a-, b-and c-secretases generate a soluble ectodomain (sAPP), carboxy terminal fragments (CTFs) and an APP intracellular C-terminal domain (AICD), Which occurs after O-glycosylation during APP transport through the Golgi complex or in the compartments subsequent to trans-Golgi of the APP secretory pathway (Tomita et al. 1998) . The b-secretase cleavage generates b-CTFs fragments, C99/100 and C89 and a cleavage generates the fragment C83, whereas the c cleavage gives rise to fragments C59-57, or AICD (Schettini et al. 2010) .
Despite its key role in the molecular neuropathology of AD, increasing evidence indicate that APP is a neuroprotective factor in acute ischemic stroke (Hefter and Draguhn 2017) . On the other hand, ischemic stroke also alters APP expression and processing (Hiltunen et al. 2009 ). Furthermore, ischemic stroke induces an increase in b-secretase activity and b-site APP cleaving enzyme (BACE) expression and thus inhibition of BACE may have a therapeutic effect on stroke (Wen et al. 2004) . Interestingly, inhibition of c-secretase reduces ischemic stroke-caused brain injury and improves functional outcome (Arumugam et al. 2006) . These studies suggest that modulation of APP expression and processing via appropriate agents may be a therapeutic strategy for stroke.
Opioid receptors (ORs) are widely distributed throughout the nervous system, which consist of three major types: d-opioid receptor (DOR), l-opioid receptor (MOR) and j-opioid receptor (KOR) (Stein et al. 2003) . Many preclinical studies have shown that opioid receptor agonists play a neuroprotective role in ischemic stroke. For instance, (D-Ala2, D-Leu5)-enkephalin, a selective DOR agonist, increases neuronal survival (Su et al. 2007; Wang et al. 2011) , promote beneficial activation of astrocytes , regulate neurogenesis ) and enhance antioxidative enzyme activity (Yang et al. 2009) following ischemia. BRL52537, kappa-opioid receptor (KOR) agonist, exerts neuroprotective effects partially through up-regulation of STAT3 activation and downregulation of caspase-3 expression after stroke (Fang et al. 2013) . Salvinorin A, a non-opioid kappa opioid receptors (KOR) agonist, protects against cerebral ischemia-induced brain injury by modulating AQP4 expression (Xin et al. 2016 ) and preservation of cerebrovascular autoregulation (Wang et al. 2012 ). EM1 and EM2 are endogenous l-opioid receptor (MOR) agonists, which enhance mitochondrial respiratory activity against oxidative stress during brain ischemia/reperfusion (I/R) (Feng et al. 2008) . Biphalin, a highly potent, non-selective OR agonist, reduces glutamate neurotoxicity and oxidative stress following ischemia (Yang et al. 2015) . These studies indicate that OR agonists may be valuable therapeutic agents for treating ischemic stroke caused problems.
Here we chose to study the therapeutic effect of Tan-67, a selective non-peptidic DOR agonist in ischemic stroke mice. Pre-treatment of Tan-67 is neuroprotective in both in vitro and in vivo models of ischemic stroke (Zhao et al. 2006; Tian et al. 2013) . However, whether post-ischemic treatment of Tan-67 is neuroprotective remains unknown. We therefore examined the effect of post-ischemic Tan-67 treatment on cerebral I/R caused brain injury and on APP expression and processing as well as secretase activities in different brain regions (penumbral cortex and ischemic cortex) at different time points following stroke. In addition, naltrindole, a selective d-opioid receptor antagonist, was used to determine whether the neuroprotective effects of post-ischemic Tan-67 are due to activation of delta opioid receptor.
Materials and methods

Animals
Adult C57BL/6J male mice (2-3 months of age, mean body weight 25 g) were purchased from Jackson Laboratories (RRID IMSR_JAX:000664, Bar Harbor, ME, USA). Animals were randomly separated into the vehicle group, Tan-67 treatment group, or sham group using an online tool (http://www.graphpad.com/quic kcalcs/). Mice were maintained in a 12 h light/dark cycle (lights on from 8 AM to 8 PM) in an air-conditioned (23 AE 2°C) room with food and water available ad libitum. All experimental procedures were approved by the Institutional Animal Care and Use Committee of the University of South Dakota (Permit Number: A-3207-01) and were in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals.
Transient middle cerebra artery occlusion (MCAO) ischemic stroke model Focal cerebral ischemia was induced according to the method described in our previous study (Min et al. 2017) . Isoflurane was used as the animal inhalation anesthetic agent in both short and lengthy procedures due to its short induction and recovery time and the reliability of its effects. It does not sensitize the myocardium to catecholamines, and it thus spares cardiac output more than other volatile agents (Gargiulo et al. 2012) . Accordingly, anesthesia of mice was initially inhaled with 5% isoflurane (95% oxygen) and was then maintained at 1.5% isoflurane. Body temperature of the mice is maintained constant during surgery using a heating pad. To perform the surgery, a midline neck incision was made and the left common and external carotid arteries were isolated and ligated. A 20 mmlong 7-0 silicon-coated monofilament suture (7020910PK5Re; Doccol Corporation, Sharon, MA, USA) was introduced into the left internal carotid artery through the common carotid artery to block the origin of the MCA, Doppler blood flowmeter (Vasamed, Eden Prairie, MN, USA) was used to confirm MCA occlusion. After 60 min of ischemia, the suture was withdrawn and reperfusion was achieved. Mice showing < 20% of baseline regional cerebral blood flow in the MCA territory after occlusion and > 70% of baseline after reperfusion were considered as a successful reperfusion. In addition, when mice regained complete consciousness, their neurological deficit was evaluated using a 5-point scale as previously described (Atochin et al. 2003) . Only the animals with scores between 2 and 3 were included in the experiments. Those mice with score 1, indicating unsuccessful MCAO, or 4, indicating less chance of survival, were euthanized and excluded from the experiments. Mice in the sham group were subjected to the same procedure except that the MCA was not occluded.
Drug administration
Drug treatment experiments were carried out in a blinded manner such that the experimenters did not know the identity of each agent. A single dosage of Tan-67 (T5824; Sigma-Aldrich, St. Louis, MO, USA) (3 mg/kg) was administered via the tail vein at 1 h before ischemia (Fig. 1a) or a different dosage of Tan-67 (1.5, 3 or 4.5 mg/ kg) was administered 1 h after ischemia (Fig. 1c) . Alternatively, naltrindole (N115; Sigma-Aldrich, 5 mg/kg), a selective d-opioid receptor antagonist, was administered via the tail vein at the beginning of reperfusion and 1 h in prior to Tan-67 treatment (Fig. 1e) . The sham and vehicle groups received the same volume of saline as the treatment groups.
Infarct volume measurement 48 h following I/R, animals were perfused trans-cardially with phosphate-buffered saline (PBS) under deep anesthesia. The brains were removed and sectioned into 2 mm slices and were then immersed into 2% TTC (T8877; 2, 3, 5-triphenyltetrazolium chloride monohydrate, Sigma-Aldrich) solution at 37°C for 5 min, which was followed by incubation into 4% paraformaldehyde for overnight. The infarct volume was traced and analyzed using the Image J software (National Institute of Health) as described previously (Min et al. 2017) .
Animal body weight and behavior assessment
To test whether Tan-67 promotes functional recovery after stroke, the mice were allowed to survive until day 7 and received daily Tan-67 injection (3 mg/kg). During this period of time, measurements of animal body weight, survival rate and a battery of behaviors (Chen et al. 2001 (Chen et al. , 2005 were performed at 1, 3, 5 and 7 days following MCAO by an investigator who was blinded to the experimental groups.
Nissl staining and cell counting
For minimizing the numbers of animals used, animals were perfused with PBS followed by 4% paraformaldehyde after they finished the behavior tests for 7 days following MCAO under deep anesthesia. The brains were removed for Nissl staining by following the standard protocol (Min et al. 2015) . For each animal, 3-6 coronal sections were used for Nissl staining. Six random visual fields of the ischemic core region were photographed under a 40 9 objective lens (RRID 490023-0007-000; Zeiss) in each section. The total number of Nissl stained cells in each field was counted using the ImagingPro-Plus software (Media Cybernetics, USA). The data were represented as the total number of cells per visual filed.
Western blot analysis The brain samples (penumbral and ischemic cortex) were collected at 6 and 24 h following stroke and were used for western blot analysis according to a previous study (Adegoke et al. 2017) . Blots were probed with an anti-BACE (1 : 1000, 5606S, RRI-DAB_1903900, Cell Signaling Technology, Danvers, MA, USA), anti-Amyloid Precursor Protein (C-terminal) (1 : 1000, A8717, RRIDAB_258409, Sigma-Aldrich), or anti-actin (1 : 1000, sc-7210, RRID AB_2223518, Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibody, or appropriate secondary antibodies conjugated with fluorescent dyes (1 : 5000, C-1003, LI-COR Inc., Lincoln, NE, USA). Protein band intensities were measured using an Odyssey scanner (LI-COR) and quantified using UN-SCAN-IT gel6.1 software (Silk Scientific Inc., Orem, UT, USA). The total APP level (APPtot) was calculated as "APPtot = APPm + APPim" that was normalized to actin, whereas the ratios of APPm/APPim and APP CTF/APPtot normalized to actin were compared between each group.
b-secretase activity assay
The ipsilateral penumbral and ischemic cortex from fresh brain hemisphere were harvested in 20 volumes of PBS and were immediately frozen in dry ice. After addition of an equal volume of 2X lysis buffer (1X PBS containing 2% Nonidet P-40 and 1% sodium deoxycholate) to the frozen tissues, the tissues were homogenized and the homogenates were then incubated on ice for 60 min with intermittent vortexing. The extracts were centrifuged at 12 000 g for 20 min and supernatant protein concentrations were determined by a Nano-Drop (ND-2000; ThermoFisher, Schaumburg, IL, USA). 40 lg proteins of extracts were incubated at 37°C for 2 h in 200 lL of assay buffer containing 20 mmol/L HEPES, 10% glycerol, 2 mmol/L DTT and one microliters of fluorogenic substrates of b-secretase (Calbiochem, Darmstadt, Germany). Fluorescence was detected using a plate reader (2030-00020; Perkin-Elmer Victor) with an excitation wavelength of 355 nm and an emission wavelength of 460 nm. The background fluorescence from each sample was subtracted from the measurements in the final analysis.
Statistical analysis
GraphPad Prism Statistical Software version 6.0 (La Jolla, CA, USA) was used for statistical analysis and graphical display. The primary outcome for stroke experiments was infarct volume, which was used to determine the group size for each experiment based on our preliminary experiments. We planned a study of a continuous response variable from independent control and experimental subjects with one control per experimental subject. In a previous study, the response within each subject group was normally distributed with standard deviation 8.258034. If the true difference in the experimental and control means was 15.39912, we would need to study six experimental subjects and six control subjects to be able to reject the null hypothesis that the population means of the experimental and control groups were equal with probability (power) 0.8. The Type I error probability associated with this test of this null hypothesis was 0.05. All numerical data were presented as mean AE SEM. Significant differences between two groups were analyzed using Student's t-test. Significant differences between more than two groups were analyzed using one-way ANOVA followed by Tukey's post hoc analysis. p < 0.05 was considered statistically significant. We hypothesized that our data followed a normal distribution, and the hypothesis would be rejected if our evidence was against it. We did not perform a test for outliers on our data.
Results
Post-ischemic treatment of Tan-67 reduces the infarct volume following ischemic stroke Since previous data have shown that Tan-67 (3 mg/kg) preconditioning decreases brain infarct volume after permanent MCAO (Zhao et al. 2006) . To verify the neuroprotective effect of the compound on mouse brain in our ischemic stroke mouse model, we first administered the same dose of Tan-67 (3 mg/kg) via the tail vein injection at 1 h in prior to ischemia. Consistent with previous studies, we found that Tan-67 pre-treatment significantly reduced the infarct volume (p < 0.01, Fig. 1a and b) . Furthermore, to determine whether a post-ischemic treatment of Tan-67 is still beneficial to the brain, animals were treated with different doses of Tan-67. When the mice were treated with Tan-67 at a dose of 3 mg/kg or 4.5 mg/kg, they showed significant reduction of infarct volume (p < 0.05, p < 0.01, Fig. 1c and d, respectively). As Tan-67 at 3 and 4.5 mg/kg showed a similar effect, we elected 3 mg/kg as the dosage for all other experiments. Conversely, the selective opioid receptor antagonist, naltrindole (5 mg/kg), abolished the neuroprotective effect exerted by Tan-67 ( Fig. 1e and f) . These results indicate that post-treatment of Tan-67 reduces infarct volume via activation of DOR following ischemic stroke.
Tan-67 improves neurological outcomes
Following surgery procedure, the body weight of Tan-67-and vehicle-treated mice was monitored from day 0 to day 7. As shown in Fig. 2a , both Tan-67 and vehicle groups of animal rapidly lost their body weights following I/R. There was no significant difference between the two groups within 7 days following stroke. However, Tan-67 treatment promoted animal survival compared with the vehicle treatment (Fig. 2b) . To evaluate whether Tan-67 enhances animal functional recovery, animals were assessed using a modified neurological score system that assesses both animal motor and sensory deficits following MCAO (Chen et al. 2001 (Chen et al. , 2005 . Mice treated with Tan-67 showed more rapid functional recovery than the control group: Tan-67 significantly enhanced functional recovery after 3 days, which persisted until 7 days (p < 0.05, Fig. 2c ). Thus, posttreatment of Tan-67 enhances animal survival and functional recovery following ischemic stroke.
Tan-67 treatment reduces neuronal cell death
Neuronal cell loss in the ipsilateral ischemic cortex was identified by Nissl staining 7 days after I/R. As expected, MCAO procedure significantly reduced the number of cells and resulted in shrinkage and irregularly arranged neurons compared with the contralateral cortex (Fig. 3a) . Cell loss caused by MCAO was rescued, at least partially, by Tan-67 treatment (p < 0.01, Fig. 3a and b) , indicating post-treatment of Tan-67 reduces neuronal loss following the procedure.
Tan-67 increases both total APP and mature APP (APPm) levels and APP processing at an early time point (6 h), but decreases their levels at a late time point (24 h) in the penumbral cortex following MCAO We next asked whether post-ischemic treatment of Tan-67 affects APP expression, maturation and processing following MCAO. Accordingly, we examined the levels of both mature (APPm) and immature (APPim) APP as well as the C-terminal fragment (CTF) of APP at 6 and 24 h following MCAO in the penumbral cortex (or peri-ischemic cortex) based on TTC staining. APP expression was reflected by the total APP level (APPm plus APPim). MCAO induced remarkable reduction in both total APP level and APPm/APPim ratio in the penumbral cortex at 6 h after MCAO (Fig. 4a and b) . However, APPm/APPim ratio and total APP level were significantly increased in the penumbral cortex, which was associated with increased CTF levels (normalized against total APP levels), in the Tan-67-treated MCAO mice compared with vehicle-treated mice. In contrast, Tan-67 induced an increase in APPm/APPim ratio, total APP and CTF levels was reversed by naltrindole (p < 0.05, Fig. 4a and b) .
At 24 h, APPm/APPim ratio and total APP level were significantly decreased in Tan-67 treated group compared with vehicle group and naltrindole plus Tan-67-treated group following MCAO (p < 0.05, Fig. 4e and f) . However, Tan-67 and naltrindole treatment did not alter BACE-1 expression at any time points examined (Fig. 4c, d, g and h) . Thus, postischemic treatment of Tan-67 increases APP expression, maturation and processing at an early time point, whereas it reduces their levels at a late time point in the penumbral cortex following I/R.
Tan-67 also increases both the total APP and APPm levels but reduces BACE-1 expression at a late time point (24 h) in the ischemic core following MCAO At 6 h following ischemic stroke, compared to vehicle treatment and naltrindole plus Tan-67-treated group, Tan-67 treatment significantly decreased APPm/APPim ratio and total APP in the ischemic core (p < 0.05, p < 0.001 Fig. 5a and b). Tan-67 treatment did not alter BACE-1 expression level at 6 h after MCAO (Fig. 5c and d) . At 24 h following MCAO, the total APP level in Tan-67-treated mice increased compared to that in vehicle-treated and naltrindole plus Tan-67-treated mice in the ischemic core (p < 0.01, Fig. 5e and  f) . Interestingly, Tan-67-treated mice showed a significant lower BACE-1 level in ischemic cortex compared with the vehicle-treated and naltrindole plus Tan-67-treated mice at 24 h after MCAO (p < 0.01, p < 0.001 Fig. 5g and h) . These results indicate that activation of DOR increases total APP levels in a delayed manner in ischemic core following ischemic stroke.
Post-treatment of Tan-67 reduces b-secretase activity in ischemic cortex at 24 h following ischemic stroke Finally, we assessed the b-and c-secretase activities in the ipsilateral penumbral and ischemic cortex at 6 and 24 h after MCAO in each group of animal. b-secretase activity was not significantly altered by Tan-67 treatment in the ipsilateral penumbral cortex at different time points (Fig. 6a) . However, Tan-67 treatment remarkably reduced b-secretase activity in the ipsilateral ischemic cortex at 24 h after MCAO compared with the vehicle treatment (Fig. 6b) . This effect was significantly attenuated by naltrindole (p < 0.05, Fig. 6b ). Intriguingly, c-secretase activity in the Tan-67 treated animals did not differ from other groups of mice either in penumbral cortex or in ischemic core (Data not shown). Thus, Tan-67 reduces of b-secretase activity in ischemic core at a late time point.
Discussion
Using a mouse stroke model, we here demonstrated that preischemic treatment of mice with a selective non-peptidic dopioid receptor agonist, Tan-67, reduced cerebral infarct size induced by MCAO. This result is in accordance with two previous observations that injection of the d-opioid receptor (DOR) agonist Tan-67, into the lateral cerebroventricle 30 min in prior to MCAO significantly alleviated neuronal injury in MCAO rats (Tian et al. 2013) , and that pretreatment of hippocampal slice cultures with Tan-67 increased ischemic tolerance (Zhao et al. 2006) . More importantly, we also demonstrated that post-ischemic treatment of MCAO mice with Tan-67 (3 mg/kg) administered peripherally was also neuroprotective as seen by decreased neuronal injury, reduced animal mortality and enhanced animal functional recovery. However, Tan-67 mediated neuroprotection was completely abolished by the administration of a selective d-opioid receptor antagonist, naltrindole, in the study. Therefore, the data strongly suggest that when administered post-ischemically, Tan-67 can exert potent neuroprotection through the activation of DOR. Thus, our data provide evidence that Tan-67 is a potential therapeutic agent for ischemic stroke.
One question raised from this study is how Tan-67 exerts its neuroprotection against ischemic stroke-induced neuronal injury. As we discovered that the neuroprotective effect of Tan-67 was associated with its modulation of APP expression, maturation and processing, it is possible that Tan-67-mediated neuroprotection may through its up-regulation of APP expression and processing. Indeed, APP participates in a number of important functions in the brain, including synaptic function and cellular response to stress (Panegyres 2001) .
Numerous studies have suggested that APP is a neuroprotective factor in acute neuronal insults, including acute hypoxiaischemia, traumatic brain injury and excitotoxicity (Hefter and Draguhn 2017) . Our data demonstrated that MCAO induced evident decrease in APP level compared with the sham-control at 6 h, whereas Tan-67 treatment attenuated MCAO-induced APP decrease and this effect could be reversed by naltrindole. As the altered intracellular neuroprotective molecules in early phase (such as 6 h) following MCAO may be critical to achieve neuroprotection, Tan-67-mediated up-regulation of total APP, APPm and APP processing may play a significant role in its induced neuroprotection observed here. Given the fact that increased APP level protects neurons against excitotoxic and ischemic damage both in vitro (Goodman and Mattson 1994) and in vivo (Bowes et al. 1994; Masliah et al. 1997; Clarke et al. 2007) , Tan-67 mediated DOR-dependent neuroprotection following I/R may be, at least partially, via modulation of APP expression/processing. However, whether the APP expression/processing alterations caused by Tan-67 treatment is causal to the outcomes observed remains to be investigated.
At 24 h, we observed MACO-induced increase in APP level in the penumbral cortex. This was in accordance with previous reports showing that APP protein or mRNA expression is increased after 1 or 2 days following ischemic stroke (Kim et al. 1998; Shi et al. 2000; Hiltunen et al. 2009 ). The observation showing that activation of DOR by Tan-67 reduced total APP and APPm levels at 24 h indicates the possibility that a high APP level is no longer required for neuroprotection in late phase (such as after 24 h) following MCAO. On the contrary, after 24 h, a persistent high level of APP or APPm may be harmful for neuronal recovery and survival in the penumbral region, as they can produce increased level of toxic Ab peptides to induce neuronal death.
It is also possible that Tan-67-mediated neuroprotection is through modulation of BACE-1 expression and b-secretase activity. There was a tendency toward increase in APP CTF either in vehicle or naltrindole plus Tan-67-treated group compared to Tan-67 alone treated group in the ischemic core at 24 h following MCAO. Additionally, we also observed that I/R up-regulated BACE-1 expression and b-secretase activity both in vehicle and naltrindole plus Tan-67-treated groups, whereas Tan-67 alone appeared to suppress BACE-1 up-regulation and b-secretase activity. Taken together, these data suggest that BACE-1 cleavage of APP was at least partially inhibited by Tan-67. These observations are also in accordance with previous studies showing that BACE-1 protein and b-secretase activity were increased in the ischemic cortex, and BACE-1 was strongly associated with apoptotic cells (Wen et al. 2004) . Moreover, activation of BACE-1 enhances caspase activation and DNA fragmentation, as observed in AD brains (Hugon et al. 2000; Fukumoto et al. 2002; Rohn et al. 2002) . Thus, suppression of BACE-1 and b-secretase activity by Tan-67 is neuroprotective in late phase following I/R, although whether b-secretase activity change caused by Tan-67 is causative to the altered APP expression/processing remains uncertain.
In summary, our data indicate that post-ischemic administration of Tan-67, a non-peptide d-opioid receptor agonist, confers DOR-dependent neuroprotection, as shown by reduced infarct size and cell death, improved animal survival, as well as enhanced functional recovery. Moreover, we also provide data showing that Tan-67 treatment is associated with altered APP expression, maturation and processing following ischemic stroke. These results indicate that Tan-67 is likely a therapeutic agent for treating ischemic stroke, and that the neuroprotective role of Tan-67 may link to its modulation of APP expression and processing. All numerical data are shown as meanAE SEM; n = 6 mice. *p < 0.05, **p < 0.01, ***p < 0.001. Fig. 6 Effect of Tan-67-mediated activation of DOR on b-secretase activity in the ischemic cortex after MCAO. (a) b-secretase activity did not show significant difference in the ipsilateral penumbral cortex between each group of mice at 6 and 24 h after MCAO. (b) b-secretase activity was significantly increased in the ipsilateral ischemic cortex of vehicle-treated and naltrindole plus Tan-67-treated mice compared with that of sham surgery mice at 24 h following MCAO, but Tan-67-treatment inhibited the increase. Data are shown as mean AE SEM; n = 3 mice. *p < 0.05.
